Literature DB >> 26735856

Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.

Junji Shibahara1, Akimasa Hayashi, Kento Misumi, Yoshihiro Sakamoto, Junichi Arita, Kiyoshi Hasegawa, Norihiro Kokudo, Masashi Fukayama.   

Abstract

The aim of this study was to elucidate the clinicopathologic characteristics of hepatocellular carcinoma with reactive ductule-like components (HCC-RD), corresponding to combined hepatocellular-cholangiocarcinoma (CHC) with stem cell features, typical subtype. Retrospective clinicopathologic analysis was performed on HCCs surgically treated at the University of Tokyo Hospital between 1995 and 2013. RD components were defined as neoplastic ductular structures composed of small "stem/progenitor-like" cells. There were 46 HCC-RDs, comprising about 3% of all HCCs. Thirty-eight cases of CHC, classical type (classical CHC), were identified during the study period. When compared with conventional HCC, HCC-RD was characterized by younger patient age (P=0.016), higher frequency of female patients (P<0.001), and higher serum α-fetoprotein levels (P=0.005). Serum carbohydrate antigen 19-9 elevation was also more frequently observed in HCC-RD than in conventional HCC (P=0.002). Histologically, clear cell constituents and interstitial fibrosis were more frequent in HCC-RD than in conventional HCC (P=0.003 and <0.001, respectively). When compared with HCC-RD and conventional HCC, classical CHC was characterized by a poorly differentiated HCC component, frequent vascular invasion, and lymph node metastasis (P<0.05). There was little prognostic difference between HCC-RD and conventional HCC, whereas overall and disease-free survival in classical CHC was significantly worse than in conventional HCC. In conclusion, although HCC-RDs do have some unique clinicopathologic characteristics, they have no prognostic significance, and it is not reasonable to include these tumors in the CHC category.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26735856     DOI: 10.1097/PAS.0000000000000579

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.

Authors:  Seong Kyun Na; Gwang Hyeon Choi; Han Chu Lee; Yong Moon Shin; Jihyun An; Danbi Lee; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

2.  Clinical features and diagnostic imaging of cholangiolocellular carcinoma compared with other primary liver cancers: a surgical perspective.

Authors:  Hiroyuki Takamura; Ryousuke Gabata; Yoshinao Obatake; Shinichi Nakanuma; Hironori Hayashi; Kazuto Kozaka; Motoko Sasaki; Mitsuyoshi Okazaki; Takahisa Yamaguchi; Hiroyuki Shimbashi; Shiro Terai; Koichi Okamoto; Isamu Makino; Jun Kinoshita; Keishi Nakamura; Tomoharu Miyashita; Hidehiro Tajima; Itasu Ninomiya; Sachio Fushida; Azusa Kitao; Masaaki Kitahara; Kuniaki Arai; Taro Yamashita; Tatsuya Yamashita; Hiroko Ikeda; Yasunori Satoh; Kenichi Harada; Syuichi Kaneko; Toshihumi Gabata; Tateo Kosaka; Tetsuo Ohta
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

3.  Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma.

Authors:  You-Yin Tang; Yu-Nuo Zhao; Tao Zhang; Zhe-Yu Chen; Xue-Lei Ma
Journal:  World J Gastroenterol       Date:  2021-11-07       Impact factor: 5.742

4.  Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study.

Authors:  Zhen Yang; Guangjun Shi
Journal:  Cancer Med       Date:  2021-12-04       Impact factor: 4.452

5.  Usefulness of 18F-FDG PET/CT and Multiphase CT in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Carcinoma-Cholangiocarcinoma.

Authors:  Jae Chun Park; Jung Gu Park; Gyoo-Sik Jung; Hee Kang; Sungmin Jun
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-11-30

6.  Histologic Assessment of Intratumoral Lymphoplasmacytic Infiltration Is Useful in Predicting Prognosis of Patients with Hepatocellular Carcinoma.

Authors:  Akimasa Hayashi; Junji Shibahara; Kento Misumi; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo; Masashi Fukayama
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.